Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Climb Bio will present pharmacokinetic and pharmacodynamic modeling for CLYM116, an anti-APRIL antibody for IgA nephropathy, at the European Renal Association Congress in June. The company will also share initial safety data from the ongoing Phase 1 study of CLYM116 in healthy volunteers.
Key figures
- Drug Name
- CLYM116, budoprutug
- Phase Of Trial
- Phase 1 (CLYM116), Phase 2 (budoprutug)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.